Combined modality therapy for unresectable stage III non-small cell lung cancer: New chemotherapy combinations

Keyphrases

• Combined Modality Therapy 100%
• Stage III Non-small Cell Lung Cancer 100%
• Thoracic Radiation Therapy 100%
• Chemotherapy Combinations 100%
• Combination Chemotherapy 50%
• Radiation Therapy 50%
• Meta-analysis 25%
• New Drugs 25%
• Non-small Cell Lung Cancer (NSCLC) 25%
• Randomized Clinical Trial 25%
• Median Survival 25%
• Carboplatin 25%
• Survival Benefit 25%
• Paclitaxel 25%
• Improved Outcomes 25%
• Clinical Evaluation 25%
• Treatment Programs 25%
• Novel Agents 25%
• Resectable Lung Cancer 25%
• Platinum-based 25%
• Chemotherapy Regimen 25%
• Survival Duration 25%
• Novel Treatments 25%
• Drug Combination 25%
• Locally Advanced Disease 25%
• Locoregional Recurrence 25%

Medicine and Dentistry

• Combination Chemotherapy 100%
• Non Small Cell Lung Cancer 100%
• Multimodality Cancer Therapy 100%
• Radiation Therapy 100%
• Clinical Trial 16%
• Meta-Analysis 16%
• Randomized Clinical Trial 16%
• Survival Rate 16%
• Recurrent Disease 16%
• Long Term Survival 16%
• Carboplatin 16%
• Paclitaxel 16%
• Combination Drug 16%
• Diseases 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Chemotherapy 100%
• Clinical Trial 25%
• Survival Rate 25%
• Randomized Clinical Trial 25%
• Carboplatin 25%
• Paclitaxel 25%
• Recurrent Disease 25%
• Long Term Survival 25%
• Combination Drug 25%
• Diseases 25%